RGD Reference Report - Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Reversal of allergen-induced airway remodeling by CysLT1 receptor blockade.

Authors: Henderson WR, JR  Chiang, GK  Tien, YT  Chi, EY 
Citation: Henderson WR Jr, etal., Am J Respir Crit Care Med. 2006 Apr 1;173(7):718-28. Epub 2005 Dec 30.
RGD ID: 4843543
Pubmed: PMID:16387808   (View Abstract at PubMed)
PMCID: PMC2662952   (View Article at PubMed Central)
DOI: DOI:10.1164/rccm.200501-088OC   (Journal Full-text)

RATIONALE: Airway inflammation in asthma is accompanied by structural changes, including goblet cell metaplasia, smooth muscle cell layer thickening, and subepithelial fibrosis. This allergen-induced airway remodeling can be replicated in a mouse asthma model. OBJECTIVES: The study goal was to determine whether established airway remodeling in a mouse asthma model is reversible by administration of the cysteinyl leukotriene (CysLT)1 receptor antagonist montelukast, the corticosteroid dexamethasone, or the combination montelukast + dexamethasone. METHODS: BALB/c mice, sensitized by intraperitoneal ovalbumin (OVA) as allergen, received intranasal OVA periodically Days 14-73 and montelukast or dexamethasone or placebo from Days 73-163. MEASUREMENTS AND MAIN RESULTS: Allergen-induced trafficking of eosinophils into the bronchoalveolar lavage fluid and lung interstitium and airway goblet cell metaplasia, smooth muscle cell layer thickening, and subepithelial fibrosis present on Day 73 persisted at Day 163, 3 mo after the last allergen challenge. Airway hyperreactivity to methacholine observed on Day 73 in OVA-treated mice was absent on Day 163. In OVA-treated mice, airway eosinophil infiltration and goblet cell metaplasia were reduced by either montelukast or dexamethasone alone. Montelukast, but not dexamethasone, reversed the established increase in airway smooth muscle mass and subepithelial collagen deposition. By immunocytochemistry, CysLT1 receptor expression was significantly increased in airway smooth muscle cells in allergen-treated mice compared with saline-treated controls and was reduced by montelukast, but not dexamethasone, administration. CONCLUSIONS: These data indicate that established airway smooth muscle cell layer thickening and subepithelial fibrosis, key allergen-induced airway structural changes not modulated by corticosteroids, are reversible by CysLT1 receptor blockade therapy.

RGD Manual Disease Annotations    Click to see Annotation Detail View
TermQualifierEvidenceWithReferenceNotesSourceOriginal Reference(s)
asthma  ISOCysltr1 (Mus musculus)4843543; 4843543 RGD 
asthma  IMP 4843543 RGD 

Objects Annotated

Genes (Rattus norvegicus)
Cysltr1  (cysteinyl leukotriene receptor 1)

Genes (Mus musculus)
Cysltr1  (cysteinyl leukotriene receptor 1)

Genes (Homo sapiens)
CYSLTR1  (cysteinyl leukotriene receptor 1)


Additional Information